Role of PGC-1α in Vascular Regulation
Implications for Atherosclerosis

Andrew O. Kadlec, Dawid S. Chabowski, Karima Ait-Aissa, David D. Gutterman

Abstract—Mitochondrial dysfunction results in high levels of oxidative stress and mitochondrial damage, leading to disruption of endothelial homeostasis. Recent discoveries have clarified several pathways, whereby mitochondrial dysregulation contributes to endothelial dysfunction and vascular disease burden. One such pathway centers around peroxisome proliferator receptor-γ coactivator 1α (PGC-1α), a transcriptional coactivator linked to mitochondrial biogenesis and antioxidant defense, among other functions. Although primarily investigated for its therapeutic potential in obesity and skeletal muscle differentiation, the ability of PGC-1α to alter a multitude of cellular functions has sparked interest in its role in the vasculature. Within this context, recent studies demonstrate that PGC-1α plays a key role in endothelial cell and smooth muscle cell regulation through effects on oxidative stress, apoptosis, inflammation, and cell proliferation. The ability of PGC-1α to affect these parameters is relevant to vascular disease progression, particularly in relation to atherosclerosis. Upregulation of PGC-1α can prevent the development of, and even encourage regression of, atherosclerotic lesions. Therefore, PGC-1α is poised to serve as a promising target in vascular disease. This review details recent findings related to PGC-1α in vascular regulation, regulation of PGC-1α itself, the role of PGC-1α in atherosclerosis, and therapies that target this key protein. (Arterioscler Thromb Vasc Biol. 2016;36:1467-1474. DOI: 10.1161/ATVBAHA.116.307123.)

Key Words: apoptosis ■ atherosclerosis ■ cardiovascular disease ■ endothelium ■ oxidative stress

The Vascular Endothelium

Endothelial cells form a continuous single-layer sheet (endothelium) lining the inside of blood vessels. The endothelium is essential in modulating vascular tone, in part, by production of vasoactive substances that act on surrounding smooth muscle cells to constrict or dilate vessels. In healthy human vessels exposed to physiological laminar flow, nitric oxide (NO) is released from endothelial cells and serves to relax vessels and maintain endothelial homeostasis. In contrast, in vessels affected by vascular pathologies, such as atherosclerosis, heart failure, and hypertension, NO bioavailability is diminished because rising levels of reactive oxygen species (ROS) react with NO or disrupt NO production, leading to impaired endothelial-dependent dilation.1–5 This resulting endothelial dysfunction is a key component of cardiovascular disease progression through impaired vaso dilatory responses and an increasingly inflammatory environment.6 Because endothelial dysfunction carries prognostic significance,7 extensive effort has been devoted to prevent or reverse this phenomenon. However, despite years of intense study and development of targeted therapies, cardiovascular diseases remain highly prevalent. A deeper understanding of involved pathways, and identification of new therapeutic targets, is thus warranted.

Although combatting vascular ROS production is a promising avenue to reduce vascular disease burden, clinical trials targeting global ROS production have been largely negative8,9; thus, alternative strategies are needed. Several cellular mechanisms contributing to vascular endothelial dysfunction have been characterized, including endoplasmic reticulum stress,10,11 high glucose levels,12 decreased formation of endothelial progenitor cells,13 and overproduction of superoxide by NADPH (nicotinamide adenine dinucleotide phosphate) oxidases.14 In addition, mitochondrial dysfunction seems to participate in the development of endothelial dysfunction, largely through excessive production of ROS by the mitochondrial respiratory chain.15,16 As a result, antioxidants targeting the mitochondria are being considered for clinical testing, including MitoQ and MitoVit-E.17,18 Instead of simply targeting a single molecule in a single pathway, one alternative approach is to identify elements that act through broad regulatory mechanisms and confer systemic protection. Peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α), a nuclear protein that regulates an array of endothelial and smooth muscle cell processes, has emerged as a promising therapeutic candidate.19 This review considers the role of PGC-1α from a vascular biology perspective and will cover mechanisms, whereby

Received on: April 21, 2015; final version accepted on: June 2, 2016.
From the Department of Physiology (A.O.K., D.D.G.); Division of Cardiology, Department of Medicine (D.S.C., K.A.-A., D.D.G.), and Cardiovascular Center (A.O.K., D.S.C., K.A.-A., D.D.G.), Medical College of Wisconsin, Milwaukee; and Department of Veterans Administration Medical Center, Milwaukee, WI (D.D.G.). Correspondence to David D. Gutterman, MD, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226. E-mail dgutt@mcw.edu
© 2016 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at http://atvb.ahajournals.org DOI: 10.1161/ATVBAHA.116.307123

1467
PGC-1α contributes to maintenance of endothelial and smooth muscle cell homeostasis, the regulation of PGC-1α itself, and strategies to boost levels of PGC-1α in the vasculature.

### Many Roles of PGC-1α

PGC-1α is a transcriptional coactivator that recruits nuclear receptors or transcription factors to regulate transcription of downstream genes in both the nucleus and the mitochondria. Instead of binding directly to nuclear or mitochondrial DNA, PGC-1α localizes in complexes containing several other proteins. The presence of multiple binding domains that enable interactions with proteins, coactivators, and RNA to orchestrate DNA-binding factors and chromatin conformation helps to orient PGC-1α at the nexus of transcriptional control. Activation of PGC-1α and resulting recruitment of this transcription machinery is elicited by cellular homeostatic cues, such as changes in metabolic status, hormone levels, and redox balance, which correspondingly activate messenger pathways, including the cellular energy sensor AMP-activated protein kinase, and cAMP.

First discovered in 1998 for its role in adaptive thermogenesis, PGC-1α–related data have amassed rapidly, demonstrating largely beneficial or protective effects in aging, obesity, diabetes mellitus, neurodegeneration, and exercise-induced changes in skeletal muscle. PGC-1α controls thermogenesis in brown fat and white-to-brown adipocyte differentiation. In skeletal muscle, PGC-1α increases insulin sensitivity and regulates fiber-type switching. Increases in PGC-1α can also prevent muscle atrophy. Repression of PGC-1α is implicated in the neurodegenerative process of Parkinson disease. These broad functional effects of PGC-1α are due, in part, to its wide distribution throughout the tissues of the body and to its ability to regulate an array of signaling pathways and transcription control elements, such as peroxisome proliferator receptor-γ (PPARγ), cAMP response element-binding protein, nuclear respiratory factor-1, forkhead box O1 (FOXO1), thyroid hormone receptor, estrogen receptor, and more. These downstream regulatory pathways are nicely reviewed by Finck and Kelly. Given the existence of PGC-1α at the core of several cellular- and organ-level homeostatic mechanisms, burgeoning interest in PGC-1α’s role in vascular biology has resulted in the generation of many exciting reports that position this protein as a key player in vascular regulation.

### PGC-1α and Vascular Biology

#### Regulation of PGC-1α in the Vasculature

The vasculature acts to match blood flow to the metabolic energy requirements of tissue. When considering the large variety of metabolic signaling pathways that converge on PGC-1α, it is evident that vascular mechanisms must be in place to control levels and activity of PGC-1α itself to establish balance between blood flow and energy expenditure. Indeed, within blood vessels, PGC-1α is responsive to a variety of inputs. Importantly, PGC-1α is increased during mechanical stimulation of the endothelium by shear stress in a sirtuin 1–dependent manner. PGC-1α levels are also regulated by endothelial vasoactive substances, such as NO and hydrogen peroxide. PGC-1α acts downstream of NO, and its regulation by this key vasodilator is time dependent. Short-term treatment (<12 hours) of endothelial cells with NO donors acts to decrease protein levels of PGC-1α, whereas long-term treatment (>24 hours) has the opposite effect. This relationship between short-term NO treatment and reduction in levels of PGC-1α was shown to be dependent on FOXO3a levels, and overexpression of FOXO3a prevents an NO-mediated decrease in PGC-1α. Interestingly, PGC-1α levels correlate with the production of hydrogen peroxide, another vasodilatory substance. Although not demonstrated in endothelial cells, hydrogen peroxide is required for the exercise-induced increase in PGC-1α in skeletal muscle.

Whether hydrogen peroxide is necessary in this same fashion in the vasculature. That PGC-1α is the target of, and can be increased by, 2 vasodilatory factors—especially one that are canonicall viewed as antagonistic—warrants further investigation of the functional vascular effects exerted by NO and hydrogen peroxide via downstream effects on PGC-1α. Further characterization is needed of mechanisms influencing PGC-1α levels or activation, including exploring connections with other vasoactive substances such as prostacyclin or thromboxane, and clarifying the mechanosensititive release of PGC-1α through cell surface receptors.

Post-translational modification is a major mechanism through which PGC-1α is regulated. Serine 570 phosphorylation and subsequent lysine acetylation in response to angiotensin II stimulation lead to inactivation of PGC-1α in vascular smooth muscle cells (VSMCs). This acetylation impairs PGC-1α–FOXO1 interactions, resulting in depressed antioxidant defense. It is important to note that angiotensin II is implicated in hypertension and atherosclerosis, providing a potential link between angiotensin II–mediated PGC-1α acetylation and cardiovascular diseases. Acetylation of PGC-1α is a bidirectional event. Silent mating type information regulation 2 homologs (Sirtuins) are histone deacetylases that have been linked to longevity and cardiovascular protection. Sirtuin 1 is a nicotinamide adenine dinucleotide–dependent histone deacetylase that increases expression of PGC-1α and promotes formation of a complex between the transcription factor FOXO3a and the PGC-1α to improve antioxidant defense. Moreover, sirtuin 1 overexpression reduces PGC-1α acetylation in the presence of oxidative stress in cultured endothelial cells. This 2-way regulation of PGC-1α via acetylation and deacetylation events exposes its importance as a homeostatic control mechanism. Micro-RNAs, small, noncoding molecules typically associated with repression of gene translation, act as another means of vascular regulation of PGC-1α. In endothelial cells, miR-19b, miR-221, and miR-222 have been shown to decrease PGC-1α expression and promote endothelial dysfunction.

---

**Nonstandard Abbreviations and Acronyms**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOXO1</td>
<td>forkhead box O1</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>PGC-1α</td>
<td>peroxisome proliferator receptor-γ coactivator 1α</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>VSMCs</td>
<td>vascular smooth muscle cells</td>
</tr>
</tbody>
</table>
of the proinflammatory cytokines, tumor necrosis factor-α and interferon-γ, resulted in mobilization of these micro-RNAs and subsequent repression of PGC-1α, establishing a direct relationship between PGC-1α and endothelial inflammation, which we discuss in further detail below.

**PGC-1α in the Vascular Endothelium**

The endothelium is responsible for regulating blood flow, largely through agonist and shear-mediated mechanisms. As stated above, shear stress on the vascular endothelium releases vasodilatory NO and stimulates the production of PGC-1α. NO and PGC-1α are known to independently combat ROS production, thereby limiting endothelial dysfunction. NO, for instance, can directly scavenge superoxide or target the mitochondrial electron transport chain to reduce levels of ROS. Likewise, PGC-1α combats excessive levels of oxidative stress by enhancing transcription of antioxidant genes, including manganese superoxide dismutase, responsible for converting superoxide in the mitochondrial matrix to hydrogen peroxide; catalase, responsible for decomposing hydrogen peroxide; and glutathione peroxidase, also responsible for diminishing hydrogen peroxide levels. Borniquel et al demonstrated that NO and PGC-1α can operate together to limit ROS levels, but the relationship is complex. Short-term NO treatment downregulates PGC-1α to reduce mitochondrial antioxidant defense gene expression, whereas long-term treatment boosts antioxidant defense through increases in PGC-1α. This time-dependent regulation of antioxidant mechanisms through PGC-1α may help to explain the known pro- and antioxidant properties of NO. An increase in antioxidant genes is only one mechanism, whereby PGC-1α stifles ROS production. ROS are also produced when mitochondrial membrane potential is hyperpolarized, leading to reduced exchange of ADP for ATP. Won et al revealed that PGC-1α can restore physiological membrane potential and dampen excessive ROS production by increasing ATP/ADP translocase activity.

PGC-1α also exerts control over angiogenesis and associated endothelial cell migration. Angiogenesis is known to require endothelial nitric oxide synthase–derived NO and endothelial ROS. Previous studies in skeletal muscle tissue demonstrate the critical role of PGC-1α in raising capillary density. However, the picture in isolated endothelial cells somewhat contrasts with the proangiogenic profile of PGC-1α in skeletal muscle. Borniquel et al discovered that PGC-1α overexpression limited NO–mediated endothelial cell migration, and treatment with NO donors decreased PGC-1α mRNA expression. These data suggest that the antioxidant properties of PGC-1α in endothelial cells are antithetical to the ROS-requiring, NO-mediated proangiogenic program. In a later study, Sawada et al reported an in vivo, endothelial-specific antiangiogenic role of PGC-1α. Mice overexpressing PGC-1α in the vascular endothelium displayed blunted reendothelialization after carotid injury. Conversely, endothelial cells isolated from PGC-1α−/− mice displayed high capacity for migration with a concurrent repression of antiangiogenic gene expression. Despite this described antiangiogenic role of endothelial PGC-1α, a recent study showed that, although endothelial cells from PGC-1α−/− mice migrate faster than those from PGC-1α+/+ mice, this migration is aberrant. Cells lacking PGC-1α do not adhere as strongly within the extracellular matrix. In addition, the cell spreading that was observed lacked proper directionality, suggesting that PGC-1α is actually required for conserved angiogenesis, in contrast to the results above. A different report illustrated the critical role of PGC-1α in driving retinal angiogenesis via vascular endothelial growth factor. Although the exact mechanism requires additional clarification, PGC-1α’s participation in both pro- and antiangiogenic responses places it at the central switch terminal for regulating vascular growth and architecture.

**PGC-1α in VSMCs**

Vascular homeostasis is not limited to contributions of the endothelial cell layer. Surrounding the endothelium are VSMCs, the ultimate effectors of vasomotion. VSMCs and endothelial cells display a dynamic interrelationship, and diffusion of endothelial substances or direct electrochemical connections can elicit responses in nearby VSMCs. Of note, PGC-1α is expressed in both the vascular endothelium and the VSMCs. Smooth muscle–specific functions of PGC-1α have been largely characterized in relation to VSMC proliferation and senescence, both of which result from excessive ROS production. In light of PGC-1α’s robust antioxidant–boosting effects in endothelial cells, it is not surprising that PGC-1α can indirectly limit ROS production in VSMCs, and conversely, loss of PGC-1α in this tissue results in a reduction in the antioxidant program. PGC-1α overexpression can reduce ROS-mediated VSMC migration. Moreover, adenosine, adenosine receptor, palmitate-, or 17β-estradiol–mediated overexpression of PGC-1α can halt ROS-mediated VSMC proliferation, even in response to exogenous stressors, such as oleic acid or elevated glucose. In addition, preventing angiotensin II–mediated inactivation of PGC-1α ameliorates VSMC senescence and hypertrophy. It seems that these antisenescent effects in VSMCs are enabled by the interaction between PGC-1α and 2 longevity-associated factors, telomerase reverse transcriptase and FOXO1. The ability of PGC-1α to enhance antioxidant gene transcription and attenuate ROS production in intimal and medial layers and to bolster antiproliferative and antiangiogenic pathways emphasizes its potential to serve as a therapeutically target for vascular disease.

**PGC-1α and Vascular Disease**

**Inflammation**

Inflammation is intimately involved in the pathogenesis of several cardiovascular disease processes, including atherosclerosis, hypertension, and heart failure. A host of factors participate in the inflammatory response. Within the vasculature, ROS are inextricably linked to the development of a proinflammatory phenotype, and we have already discussed PGC-1α’s powerful antioxidant properties. Another central pathway involves tumor necrosis factor-α, a proinflammatory signaling molecules that increases expression of downstream adhesion molecules, allowing for attachment of inflammatory response cells at sites of damage. Tumor necrosis factor-α also increases cellular ROS levels. PGC-1α is able to mitigate...
tumor necrosis factor–induced production of mitochondrial and intracellular ROS and expression of adhesion molecules throughout the vascular wall. In this same study, PGC-1α overexpression reduced the activity of NF-κB, a major effector of proinflammatory pathways. A similar effect of PGC1α on NF-κB activity was observed in muscle cells. Oxidized low–density lipoprotein is known to promote inflammation, and PGC-1α blocks oxidized low–density lipoprotein movement into cells, thereby halting the progression of inflammation. Confirmation of this anti-inflammatory effect of PGC-1α in human subjects is needed.

Atherosclerosis
That PGC-1α broadly affects diverse functions in different vascular compartments and confirms its role as a master controller of vascular homeostasis. Of particular, relevance to cardiovascular disease is its powerful induction of anti-inflammatory signals and upregulation of antioxidant proteins. Nowhere are these properties more relevant than in atherosclerosis. Once considered to be primarily a disease of lipid storage, atherosclerosis is now fundamentally considered an inflammatory process. PGC-1α is poised to reduce inflammation and, as a result, lessen atherosclerotic disease burden (Figure). On a broad, population-based scale, 1 case–control study found a higher frequency of the loss-of-function Gly482Ser polymorphism in the gene encoding for PGC-1α in patients with coronary artery disease versus control patients. Further evidence for PGC-1α’s involvement in cardiovascular disease is the decreased protein levels, albeit increased mRNA expression, of PGC-1α in vessels from patients with atherosclerosis relative to vessels from healthy subjects. When examining human atherosclerotic lesions directly, PGC-1α expression is less in symptomatic versus asymptomatic plaques. Aside from these correlative links between lower levels of PGC-1α and the presence of atherosclerosis, mechanistic studies validate PGC-1α’s atheroprotective role. In the initial stages of atherosclerosis, bone marrow–derived inflammatory monocytes invade the arterial wall, where they differentiate into macrophages. These macrophages ingest lipids and take up resident in the vascular endothelium as foam cells, forming an essential component of the atherosclerotic plaque, conferring plaque weakness, and propensity for rupture. PGC-1α is found in the human macrophages inhabiting such plaques, and PGC-1α overexpression via conjugated linoleic acid treatment can inhibit foam cell development by preventing oxidized lipid uptake into macrophages. Adopting an inverse approach, the same investigative team reported excess oxidized lipid uptake in PGC-1α−/− mice relative to wild-type controls. In contrast, results from a previous study suggest that PGC-1α deficiency did not contribute to enhanced atherosclerosis. Despite the expression of increased levels of inflammatory markers in PGC-1α−/− mice bred on an ApoE−/− background, no difference in atherosclerosis burden was observed compared with wild-type. This study showed that inflammation may be necessary but is not sufficient for promoting atherosclerosis in this model.

Xiong et al proposed that an age-dependent effect resulted in the differences between these 2 studies, stating that the atheroprotective role of PGC-1α is relevant only in older mice. In a well-designed experiment using atheroprone LDLR−/− mice, administration of wild-type or PGC-1α−/− macrophages was performed along with a high-fat diet. Mice lacking macrophage PGC-1α developed larger atherosclerotic lesions than those with intact PGC-1α. These investigators confirmed the proposed age-dependent antiatherosclerotic effects of PGC-1α by demonstrating that, indeed, young (6 months old)
PGC-1α−/− ApoE−/− mice fed a high-fat diet do not develop significant atherosclerosis, whereas a clear increase in lesion development in PGC-1α−/− ApoE−/− mice over PGC-1α+/− ApoE−/− control mice was observed at 18 months.91 Evaluation of the atheropreventive role of PGC-1α in humans is a logical next step.

Therapeutic Strategies to Increase PGC-1α

Traditional therapeutics for atherosclerosis include lifestyle changes, pharmacological therapy, and percutaneous and surgical intervention. Our most effective preventive strategies (exercise and diet) are inexpensive, but difficult to implement. Pharmacological approaches are typically associated with greater compliance, but they are often costly and address only 1 risk factor pathway. A promising advantage of targeting PGC-1α is the ability to address multiple pathways (inflammation, endothelial dysfunction, and oxidative stress) simultaneously in a single pharmacological approach. Interest in the ability to manipulate master regulators, such as PGC-1α and micro-RNAs, as a means of disease treatment is on the rise. It is important to proceed with caution: such master regulators may not serve as the best therapeutic candidates because of their ability to influence many processes, thus generating concerns about nonspecificity and unintended off-target effects on nonpathogenic pathways. Despite this concern, PGC-1α still seems to be a promising candidate in atherosclerosis in light of the discussed data. In general, an improvement in disease parameters seems to center around upregulation of PGC-1α levels or activity. Fortunately, several such strategies, distinct from current guideline-directed treatments, exist.

Calorie restriction and exercise, both known to harbor enormous potential as antiaging programs, are able to increase levels of PGC-1α and improve organismal health.80–86 likely because of cellular energy depletion, which is known to activate PGC-1α.23 Importantly, the PGC-1α–inducing effect of exercise is limited by the use of global antioxidants in untrained and trained individuals,87,88 providing a potential explanation for the inability of indiscriminate antioxidant use to ameliorate adverse cardiovascular event occurrence.8 Calorie restriction and exercise, both known to harbor enormous potential as antiaging programs, are able to increase levels of PGC-1α and improve organismal health.80–86 likely because of cellular energy depletion, which is known to activate PGC-1α.23 Importantly, the PGC-1α–inducing effect of exercise is limited by the use of global antioxidants in untrained and trained individuals,87,88 providing a potential explanation for the inability of indiscriminate antioxidant use to ameliorate adverse cardiovascular event occurrence.8 However, natural antioxidants, such as resveratrol, seem to activate PGC-1α through a reduction in overall PGC-1α acetylation.89 Lipoic acid, an endogenous antioxidant and mitochondrial cofactor known to be antiatherosclerotic,90 increases PGC-1α to counter cardiovascular disease development.87 ZLN005 is a novel transcriptional activator of PGC-1α with vasculoprotective effects in a diabetic mouse model.91 Statins can also upregulate PGC-1α in the retinal vasculature to boost antioxidant defense.92 The effect of statins on PGC-1α is tissue specific, producing PGC-1α upregulation in the heart, along with a concomitant increase in antioxidant defense, but PGC-1α downregulation in skeletal muscle.93 These examples provide new direction for novel potential therapeutic adjuncts in the treatment of atherosclerosis. Most of these treatments are already known to be beneficial in humans, but evaluation of the protective mechanism via regulation of PGC-1α instead of traditional pathways would be worthwhile. It must be considered that these treatments are nonspecific, making it difficult to predict off-target effects of using these therapeutics. Systemic approaches may also pose an issue because of the ubiquitous expression of PGC-1α in tissues, such as liver, heart, adipose, and muscle. However, as activation or upregulation of PGC-1α is beneficial in relation to several disease processes,94–96 this concern may not present a major obstacle and may actually be advantageous in aging patients or subjects with multiple comorbidities.

Several other caveats must be mentioned in the discussion of PGC-1α’s therapeutic potential. For example, forced PGC-1α overexpression has also been associated with detrimental off-target effects. One study reported that excessive overexpression of PGC-1α produced reversible cardiomyopathy in mice as a result of robust mitochondrial biogenesis in cardiac tissue95; in contrast, modest (2-fold) elevations in cardiac PGC-1α expression do not allow for preservation of cardiac function.96 Others have reported a protumorigenic effect of PGC-1α,97 likely as a result of improvements in cell survival, although a recent study suggests that PGC-1α may actually suppress tumor formation.98 Therefore, caution must be used when attempting to overexpress PGC-1α.

Future Directions

Future studies should continue to characterize PGC-1α’s therapeutic potential. One lingering issue is the identification of a physiological range of PGC-1α upregulation in cardiovascular system in light of the previously mentioned reports of dose-dependent cardiotoxic effects. Furthermore, much work needs to be done to elucidate how to most effectively target PGC-1α, either through regulation of expression or through post-translational modification. It is currently difficult to speculate as to the most effective method of promoting PGC-1α’s protective effects, although most studies report a beneficial effect of boosted expression.

Although investigators should continue to identify the molecular routes through which PGC-1α acts in the vasculature, it will also be important to integrate PGC-1α signaling with other signaling pathways, as was done by Xiong et al99 in characterizing the interaction between PGC-1α and telomerase. When performing these investigations, it will be critical not only to explore these relationships within the endothelial and smooth muscle cell layers but also to extend this work into the adventitial layer, an increasingly recognized contributor to vascular disease.99 Similarly, we must strive to connect PGC-1α with other outcome variables in vascular disease, such as endothelial permeability, vascular stiffness and calcification, and the venous circulation. Another intriguing potential connection to explore is that between the PGC-1α and the other pathways producing endothelial dysfunction, such as endothelial progenitor cell deficiency, high glucose, and endoplasmic reticulum stress. Doing so will provide further support for translating these findings to human subjects.

Summary and Conclusions

To effectively combat atherosclerosis, we must understand both the fundamental mechanisms contributing to the disease and options to combat disease development or to induce disease regression. When considering the data demonstrating PGC-1α’s ability to act as a master regulator of cell function
and counteract oxidative stress, lesion development, endothelial dysfunction, VSMC proliferation, and inflammation, this protein emerges as an attractive therapeutic candidate for atherosclerosis. Its broad localization, regulation, and functional significance highlight its potential. Because interest in PGC-1α’s role in the vasculature continues to rise, further clarification of the involved pathways may lead to an improved ability to manipulate this pathway. Understanding PGC-1α will help us to better understand the atherosclerotic process and the manner in which endothelial function is altered by disease from a novel angle.

Acknowledgments
We thank Dr Alison Kriegel and Mark Paterson for the critical review of this article.

Sources of Funding
This work was funded by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) grant 4RO1HL113612-04 (D.D. Gutterman).

Disclosures
None.

References


37. Silveira LR, Pilegaard H, Kasuwalla K, Curi R, Hellsten Y. The contraction induced increase in gene expression of peroxisome proliferator-activated receptor (PPAR) coactivator-1alpha (PGC-1alp) and mitochondrial uncoupling protein 3 (UCP3) and hexokinase II (HKII) in primary rat skeletal muscle cells is dependent on reactive oxygen species. *Biochim Biophys Acta*. 2006;1763:969–976. doi: 10.1016/j.bbamcr.2006.06.010.


87. Several co-activator 1 alpha (PGC-1alpha) expression in mice. 2005;434:113–118. doi: 10.1038/nature03354.


Role of PGC-1α in Vascular Regulation: Implications for Atherosclerosis
Andrew O. Kadlec, Dawid S. Chabowski, Karima Ait-Aissa and David D. Gutterman

Arterioscler Thromb Vasc Biol. 2016;36:1467-1474; originally published online June 16, 2016;
doi: 10.1161/ATVBAHA.116.307123

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272
Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://atvb.ahajournals.org/content/36/8/1467

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2016/06/16/ATVBAHA.116.307123.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for
which permission is being requested is located, click Request Permissions in the middle column of the Web
page under Services. Further information about this process is available in the Permissions and Rights
Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online
at:
http://atvb.ahajournals.org//subscriptions/